Table 3.

Subgroup analysis of the associations between LDH and in-hospital mortality

	N	OR; 95% CI	p for interaction
Age, years
≦65	4182	1.55 (1.35–1.78)	0.286
> 65	4254	1.63 (1.45–1.84)
Sex
Female	3708	1.51 (1.32–1.72)	0.194
Male	4728	1.58 (1.40–1.78)
SOFA
≦5	4590	1.63 (1.42–1.89)	0.36
> 5	3846	1.5 (1.33–1.67)
SAPSII
≦39	4408	1.59 (1.36–1.86)	0.42
> 39	4028	1.51 (1.35–1.68)
Liver disease
Yes	1537	1.4 (1.17–1.67)	0.161
No	6899	1.57 (1.41–1.74)
Diabetes
Yes	2174	1.46 (1.22–1.76)	0.191
No	6262	1.56 (1.41–1.73)
Hypertension
Yes	3993	1.72 (1.5–1.98)	0.167
No	4443	1.43 (1.28–1.61)
Chronic heart failure
Yes	2877	1.48 (1.28–1.72)	0.213
No	5559	1.58 (1.41–1.76)
Stroke
Yes	756	1.42 (1.08–1.87)	0.234
No	7680	1.58 (1.43–1.73)
Coronary heart disease
Yes	2118	2.03 (1.64–2.52)	0.157
No	6318	1.47 (1.33–1.63)
Chronic pulmonary
Yes	1986	1.52 (1.26–1.85)	0.219
No	6450	1.56 (1.4–1.72)
Vasopressin use
Yes	926	1.59 (1.3–1.94)	0.3
No	7510	1.52 (1.38–1.69)
Ventilator use
Yes	3591	1.47 (1.31–1.66)	0.223
No	4845	1.64 (1.42–1.88)
CRRT
Yes	378	1.51 (1.13–2.02)	0.653
No	8058	1.6 (1.46–1.76)
AKI stage
Stage 1	3404	1.66 (1.38–2.01)	0.321
Stage 2	3445	1.51 (1.31–1.75)
Stage 3	1587	1.41 (1.17–1.66)